$ENTX

Entera Bio Ltd.

Entera Bio is a clinical-stage company developing oral peptide and protein replacement therapies for chronic medical conditions. Its N-Tab platform is designed to stabilize peptides in the gastrointestinal tract and promote their absorption into the bloodstream. The pipeline includes EB613, an oral PTH(1-34) tablet being developed for osteoporosis; EB612, an oral PTH tablet for hypoparathyroidism; EB618, an oral GLP-1/glucagon dual-agonist program for obesity and metabolic and fibrotic disorders; and an oral GLP-2 program for short bowel syndrome and other disorders involving malabsorption or mucosal inflammation. Entera advances product candidates through research and clinical development and collaborates with OPKO on programs including oral PTH, GLP-1/glucagon and GLP-2. Under its oral GLP-1/glucagon collaboration, Entera and OPKO share development costs and proceeds under agreed terms. Entera is headquartered in Jerusalem.

No enriched coverage for $ENTX in the last 7 days.

No SEC Form 4 filings for $ENTX in the last 30 days.

See all $ENTX insider activity →
High

Entera Announces Third Quarter 2026 Financial Results and Business Updates

Entera Bio Ltd. (ENTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Entera Announces Third Quarter 2026 Financial Results and Business Updates Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership Expanded with Appointment of Senior Exe

ENTX sentiment & insider activity

Recent ENTX coverage spans corporate actions, earnings and financial news.

What's driving ENTX

AlphAI scores every news story that mentions ENTX with an AI model for sentiment and relevance, and aggregates insider trades from Entera Bio Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ENTX

Score
$ENTXMedAI 8/10

A planned osteoporosis pill trial is expected to enroll about 900 women. Entera expects its first site to open in late 2026.

Entera Bio (ENTX) plans to initiate a Phase 3 trial for its osteoporosis drug EB613 in late 2026, with 900 women expected to enroll. The company presented Phase 2 data at ASBMR 2026, showing potential benefits for patients with low bone mineral density. Entera also announced key leadership appointments and financial results for Q3 2026.

$ENTXLowExec change· appointed

Entera Bio Ltd. (ENTX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Entera Bio Ltd. (ENTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) He joins Entera with two d

$ENTXMedAI 8/10

Entera Bio to present Phase 3 trial design for oral osteoporosis drug

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Entera Bio Ltd. (ENTX) appointed Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill has 35 years of biopharmaceutical experience, including roles at Gilead and Amgen. She succeeds Yonatan Malca, who is stepping down. Hamill's expertise is expected to support Entera's late-stage clinical trials and commercial readiness for EB613, an oral peptide for osteoporosis.

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.

Related tickers